A Phase I/II safety and tolerability study following autologous infusion of adult haematopoietic cells to patients with acute total anterior circulation ischaemic stroke

Imperial College London0 个研究点目标入组 10 人开始时间: 2006年4月10日最近更新: 2019年11月25日

试验速览

暂无简介。

•Symptoms and signs of clinically definite acute stroke
•Time of onset is known & treatment can be started within 7 days of onset
•CT or MRI brain scanning has reliably excluded both intracranial haemorrhage and structural brain lesions which can mimic stroke (e.g. cerebral tumour)
•The stroke is severe and conforming to total anterior circulation phenotype (weakness, homonymous hemianopia and focal cognitive deficit (e.g. aphasia) or reduction in consciousness.
•An age range of 30 to 80 years of age
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Known defect of clotting or platelet function
•Haematological causes of stroke
•Severe co-morbidity
•Hepatic or renal dysfuction
•Patients with evidence of life-threatening infection (e.g. HIV) or life-threatening illness (e.g. advanced cancer)
•Patient should be excluded if blood glucose <3.0 or >20.0mmol/L
•Patient was already dependent in activities of daily living before the present stroke.
•Patients who have been included in any other clinical trial within the previous month
•Patients who are unavailable for follow-up (e.g. no fixed home address)

发起方